Evidence map›Paper›PMID 29171998›Full record

ReviewJournal of Alzheimer's disease : JAD2018

Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin.

Barbara Borroni, Alberto Benussi, Enrico Premi, Antonella Alberici, Elena Marcello, Fabrizio Gardoni, Monica Di Luca, Alessandro Padovani

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Conserved gene signatures shared amongFrontiers in molecular biosciences · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Article
  17. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Article
  18. Neuroinflammation in frontotemporal dementia.Nature reviews. Neurology · 2019
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Barbara BorroniDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Alberto BenussiDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Enrico PremiDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Antonella AlbericiDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Elena MarcelloDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Fabrizio GardoniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Monica Di LucaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Alessandro PadovaniDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
University of Brescia · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frontotemporal dementia (FTD) is a heterogeneous clinical, genetic, and neuropathological disorder. Clinical diagnosis and prediction of neuropathological substrates are hampered by heterogeneous pictures. Diagnostic markers are key in clinical trials to differentiate FTD from other neurodegenerative dementias. In the same view, identifying the neuropathological hallmarks of the disease is key in light of future disease-modifying treatments. The aim of the present review is to unravel the progress in biomarker discovery, discussing the potential applications of available biological, imaging, and neurophysiological markers.

Indexed as

BiomarkersBrainFrontotemporal DementiaHumansNeuroimagingBiomarkersBiomarkerscerebrospinal fluidfrontotemporal lobar degenerationneuroimagingtranscranial magneticstimulation

Identifiers

PMID29171998
PMCPMC5870000
OpenAlexW2770547283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.